Medifast (NYSE:MED) Director Buys $342,069.42 in Stock

Medifast Inc (NYSE:MED) Director Parsa Kiai purchased 29,337 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were purchased at an average price of $11.66 per share, for a total transaction of $342,069.42. Following the purchase, the director directly owned 619,331 shares in the company, valued at $7,221,399.46. The trade was a 4.97% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Parsa Kiai also recently made the following trade(s):

• On Thursday, August 20th, Parsa Kiai purchased 43,150 shares of Medifast stock. The shares were purchased at an average cost of $11.60 per share, for a total transaction of $500,540.00.

Medifast Trading Up 0.4%

Shares of NYSE MED opened at $12.00 on Monday. The stock has a market cap of $134.16 million, a P/E ratio of -5.15 and a beta of 0.65. Medifast Inc has a twelve month low of $9.22 and a twelve month high of $14.67. The stock has a 50 day moving average of $10.92 and a two-hundred day moving average of $11.06.

Medifast (NYSE:MED) last announced its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.37. The business had revenue of $76.38 million for the quarter, compared to analyst estimates of $72.70 million. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. As a group, research analysts predict that Medifast Inc will post -1 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on MED shares. Weiss Ratings raised shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research report on Monday, August 17th. Zacks Research cut shares of Medifast from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $12.00.

Institutional Investors Weigh In On Medifast

Several large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its holdings in shares of Medifast by 103.1% during the third quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after purchasing an additional 1,187 shares during the period. Quantbot Technologies LP purchased a new position in Medifast during the 3rd quarter worth $37,000. Intesa Sanpaolo Wealth Management acquired a new stake in shares of Medifast in the 4th quarter worth $47,000. State of Wyoming acquired a new stake in Medifast in the fourth quarter valued at about $59,000. Finally, Strs Ohio acquired a new stake in shares of Medifast in the 1st quarter valued at approximately $78,000. Hedge funds and other institutional investors own 95.51% of the company’s stock.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.